Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors.
Cobleigh
M A
MA
Rush Presbyterian-St. Luke's Medical Center, Riverside, IL 60546-1827, USA.
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000517:prevention & control; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002986:Clinical Trials as Topic; D000075202:Contraindications; D004347:Drug Interactions; D004414:Dyspareunia / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000139:chemically induced; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D005483:Flushing / Q000517:prevention & control; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D019964:Mood Disorders / Q000517:prevention & control; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000139:chemically induced; D009376:Neoplasms, Hormone-Dependent / Q000139:chemically induced / Q000517:prevention & control; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000517:prevention & control; D014411:Neoplastic Stem Cells / Q000187:drug effects; D010024:Osteoporosis / Q000517:prevention & control; D016649:Primary Ovarian Insufficiency / Q000517:prevention & control; D012893:Sleep Wake Disorders / Q000517:prevention & control; D013629:Tamoxifen / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014627:Vaginitis / Q000517:prevention & control
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens; D013629:Tamoxifen